| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $27.1M | — | +61.1% |
| SG&A Expense | $4.4M | — | +7.9% |
| Operating Income | -$31.5M | — | -50.8% |
| Net Income | -$29.4M | +1.4% | -54.7% |
| EPS (Basic) | -$37.18 | — | -48.2% |
| EPS (Diluted) | -$37.18 | — | -48.2% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $64.1M | — | — |
| Short-term Investments | $163.0M | — | — |
| Current Assets | $245.3M | — | — |
| Total Assets | $257.2M | — | — |
| Current Liabilities | $18.6M | — | — |
| Total Liabilities | $23.7M | — | — |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$91.3M | — | — |
| Capital Expenditures | $97K | — | — |
| Investing Cash Flow | -$80.7M | — | — |
| Financing Cash Flow | $197.9M | — | — |
| Free Cash Flow | -$91.4M | — | — |
| Stockholders' Equity | -$274.2M | -11.9% | -59.1% |